Jaguar Health Highlights Focus on Cancer Supportive Care at ASTRO Annual Meeting

Jaguar Health, Inc. (NASDAQ:JAGX), through its subsidiary Napo Pharmaceuticals, will feature its FDA-approved Gelclair product at the ASTRO Annual Meeting from September 29 to October 2, 2024, in Washington, DC. The company aims to commercialize Gelclair in the U.S. by October 2024.

Gelclair is designed for managing pain caused by oral mucositis, a significant adverse effect of chemotherapy affecting up to 40% of patients, and up to 90% in head and neck cancer patients. Gelclair provides a soothing gel that adheres to the mucosal surface of the mouth, offering pain relief without numbing, unlike other treatments.

Oral mucositis has severe physical, social, and economic impacts, complicating patient care with increased hospitalization and treatment delays. Its economic burden is notable, with the cost of severe cases surpassing $17,244 per patient. By reducing pain and improving the ability to eat and drink, Gelclair is positioned to enhance the quality of life for those affected.